EMBO Molecular Medicine

Cover image for Vol. 8 Issue 12

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Stefanie Dimmeler (Chief Editor), Roberto Buccione and Céline Carret (EMBO Editors)

Online ISSN: 1757-4684

VIEW

  1. 1 - 7
  1. Research Articles

    1. You have full text access to this OnlineOpen article
      Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases

      Irene Sambri, Rosa D'Alessio, Yulia Ezhova, Teresa Giuliano, Nicolina Cristina Sorrentino, Vincenzo Cacace, Maria De Risi, Mauro Cataldi, Lucio Annunziato, Elvira De Leonibus and Alessandro Fraldi

      Version of Record online: 23 NOV 2016 | DOI: 10.15252/emmm.201606965

      Thumbnail image of graphical abstract

      Neurodegeneration associated with lysosomal dysfunction in lysosomal storage disorders (LSDs) may be linked to impaired presynaptic maintenance initiated by a reduction in α-synuclein and CSPα levels at nerve terminals.

    2. You have full text access to this OnlineOpen article
      Nec-1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice

      Seung-Hoon Yang, Dongkeun Kenneth Lee, Jisu Shin, Sejin Lee, Seungyeop Baek, Jiyoon Kim, Hoyong Jung, Jung-Mi Hah and YoungSoo Kim

      Version of Record online: 17 NOV 2016 | DOI: 10.15252/emmm.201606566

      Thumbnail image of graphical abstract

      Aβ plaques, hyperphosphorylated tau, brain atrophy and cognitive deficits are major hallmarks and therapeutic targets of Alzheimer's disease. A small molecule Nec-1 inhibits Alzheimer-like pathologies and behaviours of transgenic mice models by alleviating all of these phenotypes.

    3. You have full text access to this OnlineOpen article
      Coenzyme Q deficiency causes impairment of the sulfide oxidation pathway

      Marcello Ziosi, Ivano Di Meo, Giulio Kleiner, Xing-Huang Gao, Emanuele Barca, Maria J Sanchez-Quintero, Saba Tadesse, Hongfeng Jiang, Changhong Qiao, Richard J Rodenburg, Emmanuel Scalais, Markus Schuelke, Belinda Willard, Maria Hatzoglou, Valeria Tiranti and Catarina M Quinzii

      Version of Record online: 17 NOV 2016 | DOI: 10.15252/emmm.201606356

      Thumbnail image of graphical abstract

      Coenzyme Q (CoQ) is an electron acceptor for sulfide-quinone reductase (SQR), the first enzyme of the hydrogen sulfide oxidation pathway. Lack of CoQ is here shown to cause impairment of hydrogen sulfide oxidation in vitro and in vivo.

    4. You have full text access to this OnlineOpen article
      CoQ deficiency causes disruption of mitochondrial sulfide oxidation, a new pathomechanism associated with this syndrome

      Marta Luna-Sánchez, Agustín Hidalgo-Gutiérrez, Tatjana M Hildebrandt, Julio Chaves-Serrano, Eliana Barriocanal-Casado, Ángela Santos-Fandila, Miguel Romero, Ramy KA Sayed, Juan Duarte, Holger Prokisch, Markus Schuelke, Felix Distelmaier, Germaine Escames, Darío Acuña-Castroviejo and Luis C López

      Version of Record online: 17 NOV 2016 | DOI: 10.15252/emmm.201606345

      Thumbnail image of graphical abstract

      Disruption of the mitochondrial hydrogen sulfide oxidation pathway is identified as a new pathomechanism associated with primary CoQ deficiency. These findings may help explain the clinical heterogeneity of this syndrome.

  2. News & Views

    1. You have full text access to this OnlineOpen article
      After surviving cancer, what about late life effects of the cure?

      Julie Nonnekens and Jan HJ Hoeijmakers

      Version of Record online: 16 NOV 2016 | DOI: 10.15252/emmm.201607062

      Thumbnail image of graphical abstract

      While chemotherapeutics are beneficial to cancer patients, they are also responsible for side effects with devastating consequences. Transient p53 inhibition ameliorates ototoxicity without reducing cisplatin efficacy, as highlighted this month by Nonnekens and Hoeijmakers.

  3. Commentary

    1. You have full text access to this OnlineOpen article
      An evaluation of the therapeutic potential of fecal microbiota transplantation to treat infectious and metabolic diseases

      Albert K Groen and Max Nieuwdorp

      Version of Record online: 10 NOV 2016 | DOI: 10.15252/emmm.201607035

      Thumbnail image of graphical abstract

      Fecal microbiota transplantation (FMT) has had a long history in medicine for treating a number of human diseases. While it seems to work for persistent Clostridium difficile infections, results are variable for other disorders. A. Groen and M. Nieuwdorp's commentary sheds light on this issue.

  4. Research Articles

    1. You have full text access to this OnlineOpen article
      Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy

      Nesrine Benkafadar, Julien Menardo, Jérôme Bourien, Régis Nouvian, Florence François, Didier Decaudin, Domenico Maiorano, Jean-Luc Puel and Jing Wang

      Version of Record online: 28 OCT 2016 | DOI: 10.15252/emmm.201606230

      Thumbnail image of graphical abstract

      The normal tissue injuries induced by the chemotherapeutic drug cisplatin remain a major clinical problem. Here, PFT-α is shown to protect hearing without compromising the chemotherapeutic efficacy of cisplatin and even sensitizes TP53-mutant breast tumors to cisplatin.

VIEW

  1. 1 - 7

SEARCH

SEARCH BY CITATION